PATENT

The invention relates to a process for the pre- paration of £60 - and +65 -interferon by isolating the buffy coat fraction of blood, removing the erythrocytes, suspending the leukocytes in a suitable nutrient medium and treating with an +60 -interferon inducer and with a + 65 -interferon inducer, which comprises producing + 60 -interferon and + 65 -interferon one after the other in the same leukocyte culture by pre-treating the suspension obtained after the separation of the leukocyte/buffy coat/fraction of blood, removal of the erythrocytes and suspending the leukocytes in a suitable nutrient medium with +0 - or +62 -interferon, con- tacting with an +60 -interferon inducer, separating the liquid containing the +60 - interferon from the cells, if desired recovering the + 0 -interferon, washing and suspending the cells in a suitable nutrient medium, treating with a mitogenic agent, separating the liquid com- prising +60 -interferon from the cells and if desired recovering + 60 -interferon and if desired making + 60 -interferon free of + 60 -interferon. The advantage of the process is that +60 - and +6 5 -interferon are produced from the same leukocyte culture in two steps. This makes the process more economical and enables an effec- tive utilization of the limitedly available leukocytes.

469~15

P A R A T H Y M O S I N A L P H A

Bernard L Horecker assigned to Hoffmann-La Roche Inc

Parathymyosin alpha is a novel peptide isolated from mammalian thymus and contains approx- imately 105 amino acid residues. It bears a high degree of homology to prothymosin alpha both in sequence and amino acid composition. Para- thymosin alpha acts as a blocker or modulator or prothymosin alpha activity.

4698221

V A C C I N E S C O N T A I N I N G F A T S O L U B L E V I T A M I N S , Z I N C

C O M P O U N D S A N D S E L E N I U M C O M P O U N D S

ABSTRACTS 111

The invention relates to vaccines which, in addi- tion to antigens, contain fat-soluble vitamins (such as vitamins A, D or E), physiologically ac- ceptable zinc and selenium compounds and, optionally, absorption-promoting agents and/or spreading oils.

4698298

C O M P E T I T I V E I M M U N O A S S A Y P R O T O C A L F O R T A R G E T S

I N C L U D I N G L I P O P R O T E I N S A N D A L P H A - F E T O P R O T E I N

Alain Dedieu, Campbell Lockhart, Etienne Jolu, Avignon, France assigned to Commissariat a 1£3 Energie Atomique

The invention relates to a process for the immunoassay of a substance, such as an antigen, a hapten or an antibody. This process comprises the following stages: (1) contacting a sample con- taining the substance to be assayed with a label- led immunoactive reagent specific to said substance, the immunoactive reagent quantity being such that the substance to be assayed is in excess compared with that labelled immunoac- rive reagent; (2) contacting at least part of the thus obtained reaction medium with a solid phase, to which is fixed an immunoactive reagent specific to the substance to be assayed; (3) separating the reaction medium from the solid phase; and (4) determining the labelled immuno- active reagent content of the solid phase. This process is more particularly applicable to the as- saying of lipoprotein and in this case use is made of an antibody labelled by an enzyme, such as the Raifort peroxidase. It is also possible to assay £60 -foetoprotein by using monoclonal anti- bodies.

4698307

R E C O M B I N A N T D N A C L O N I N G V E C T O R S C O N T A I N I N G S E L E C T A B L E G E N E T I C M A R K E R S F O R U S E I N

S T R E P T O M Y C E S A N D R E L A T E D O R G A N I S M S

Otto C Straub, Tfederal Republic Of Germana James A Mabe, Walter M Nakatsukasa assigned assigned to Bayer Aktiengesellschaft to Eli Lilly and Company